Neutral
The Zacks Analyst Blog features Moderna, Merck, and Vertex Pharmaceuticals, highlighting Moderna's Q1 2026 earnings. Moderna reported a lower-than-exp...
Neutral
Brookline Capital Markets has slightly lowered its FY2029 EPS forecast for Moderna to $11.83, while projecting $19.45 for FY2030, indicating a short-t...
Moderna (MRNA) stock experienced a five-day losing streak, resulting in an 18% decline. The article mentions financial market data sources and disclai...
Neutral
Moderna, Inc. (NASDAQ:MRNA) has received an average "Reduce" rating from brokerages, with an average 12-month price target of $33.87. While regulatory...
Neutral
Moderna (MRNA) is slated to release its Q1 2026 earnings before market open on Friday, May 1st, with analysts forecasting a loss of ($2.03) EPS and $2...
Moderna, Inc. (MRNA) delivered a presentation at the ESCMID Global 2026 event. The company published a slide deck in conjunction with this presentatio...
Neutral
Moderna (MRNA) has initiated a Phase 3 trial for its mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018, with the first participants dosed ...
Bullish
Moderna has initiated a late-stage trial for its experimental bird flu vaccine, mRNA-1018, in the US and UK, making it the first mRNA pandemic bird fl...
Moderna has initiated a Phase 3 study for its investigational mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018, with the first participan...
Moderna has initiated a Phase 3 study for its investigational H5 pandemic influenza mRNA vaccine candidate, mRNA-1018, in the U.S. and UK, aiming to e...
Neutral
A new study presented by Sanofi at the ESCMID Global Congress revealed that its protein-based COVID-19 vaccine, Nuvaxovid, is better tolerated than Mo...
Neutral
Moderna's future hinges on whether its mRNA technology can successfully pivot beyond its COVID-19 vaccine to diversified biotech products across infec...
Bullish
Moderna Inc. is attempting to pivot beyond its COVID-19 vaccine success, leveraging its mRNA platform for new therapies in flu, RSV, cancer, and rare ...
Neutral
Moderna faces the critical challenge of demonstrating that its mRNA platform can deliver successful therapies beyond its COVID-19 vaccine. This pivot ...
Neutral
Moderna's Spikevax, initially known for COVID-19, is evolving into a broader respiratory vaccine, with the company focusing on combination shots for f...